No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
APLT240719C17500
- 0.15
- 0.000.00%
15min DelayTrading Apr 1 09:48 ET
0.00High0.00Low
0.00Open0.15Pre Close0 Volume607 Open Interest17.50Strike Price0.00Turnover393.53%IV300.23%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.1131Delta0.0514Gamma29.40Leverage Ratio-0.0211Theta0.0002Rho3.33Eff Leverage0.0018Vega
Intraday
- 5D
- Daily
News
Express News | Applied Therapeutics Was Added To The Russell 3000 Index, Effective After The U.S. Market Closed On June 28, 2024, As Part Of The 2024 Russell Indexes Annual Reconstitution
Applied Therapeutics Added to Russell 3000 Index
NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in
Why Is Applied Therapeutics, Inc. (APLT) the Best Biotech Penny Stock to Buy Now?
Here's Why We're Not Too Worried About Applied Therapeutics' (NASDAQ:APLT) Cash Burn Situation
Have Insiders Sold Applied Therapeutics Shares Recently?
We'd be surprised if Applied Therapeutics, Inc. (NASDAQ:APLT) shareholders haven't noticed that the Chair of the Board of Directors, Shoshana Shendelman, recently sold US$267k worth of stock at US$4.3
Top 4 Health Care Stocks That May Keep You Up At Night This Month
As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator
Comments
$Applied Therapeutics(APLT.US$ keep up the early momentum
$Applied Therapeutics(APLT.US$ Dip buying on consolidating aiming for highs of 7ish or 8
$Applied Therapeutics(APLT.US$
$Applied Therapeutics(APLT.US$
$Applied Therapeutics(APLT.US$ Applied Therapeutics Plans To Present Results From Phase 3 ARISE-HF Study In Diabetic Cardiomyopathy At ACC 2024
2
$Applied Therapeutics(APLT.US$ Applied Therapeutics said regulators had extended the period for reviewing its application for a rare metabolic disease treatment.
The biopharmaceutical company said Thursday that the Food and Drug Administration now has a target action date of Nov. 28 for its application, compared with the previous date of Aug. 28.
The company's application is for govorestat in the treatment of Galactosemia, a rare genetic condition that makes patients unable to metab...
The biopharmaceutical company said Thursday that the Food and Drug Administration now has a target action date of Nov. 28 for its application, compared with the previous date of Aug. 28.
The company's application is for govorestat in the treatment of Galactosemia, a rare genetic condition that makes patients unable to metab...
1
Read more